Legend Biotech rises after second quarter results beat estimates - LEGN News | RalliesLegend Biotech rises after second quarter results beat estimates
L
LEGN• Second-quarter results beat estimates
- Shares of drugmaker Legend Biotech (NASDAQ: LEGN) climbed 5.1% to $21.70 in premarket trading.
- LEGN posted second-quarter revenue of $387.5 million, above analysts' average estimate of $355.8 million, according to LSEG-compiled data.
- Second-quarter adjusted earnings per share of 16 cents beat estimates of 7 cents.
- The company reported cash and cash equivalents, and time deposits, of about $965 million as of June 30.
- Up to the last close, the stock was down about 5% year to date.
